Lupin has launched generic Paxil CR (Paroxetin) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Paxil CR Tablets had US sales of $126.4 million, as per IMS MAT December 2016.
Lupin’s Paroxetin Extended Release Tablets USP; 12.5 mg, 25 mg and 37.5 mg are the AB rated generic equivalents of Apotex Technologies, Inc’s Paxil CR Tablets, 12.5 mg, 25 mg and 37.5 mg. It is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.